Global Cryptococcosis Market to Expand at a CAGR of 4.8% from 2016 to 2024

Cryptococcosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024 The highly fragmented global cryptococcosis market is being pioneered by only a handful of players based in developed regions of the world.

Pfizer, Inc., Valeant Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Janssen Biotech, Inc. had collectively held a share of 41% in the global cryptococcosis market in terms of value, for 2015.

Their dominance in the market was marked by factors such as operating stronghold in developed economies where the demand and awareness are high, better brand name recognition, and higher investments in research and development.

One of the key factors driving the global cryptococcosis market is the increasing incidence of cryptococcosis infections across the world. The number of patients suffering from cryptococcosis has been found to be on the rise at a faster rate than previously thought. The patients suffering from the fungal infection are found to be in high numbers among HIV positive patients.

Consequently, the growing number of HIV patients is also spurring the demand for advanced and effective treatment for the disease. Rising initiatives by government and non-government organizations is also putting the pipeline development in the global cryptococcosis market on the fast track in many countries, especially in developed ones.

However, the global cryptococcosis market is currently being affected by restraining factors such as the increased mortality among cryptococcosis infected patients, which reduces the overall scope of testing and diagnostics, and the imminent patent expiry of key drugs which will result in the large scale entry of cheaper generics.

Browse Full Research Report on Cryptococcosis Market: http://www.transparencymarketresearch.com/cryptococcosismarket.html The global cryptococcosis market was valued at US$4.12 bn in 2015 and is projected to reach US$6.27 bn by 2024, after expanding at a CAGR of 4.8% from 2016 to 2024.

One of the key factors driving the global cryptococcosis market is the increasing incidence of cryptococcosis infections across the world. The number of patients suffering from cryptococcosis has been found to be on the rise at a faster rate than previously thought. The patients suffering from the fungal infection are found to be in high numbers among HIV positive patients. Consequently, the growing number of HIV patients is also spurring the demand for advanced and effective treatment for the disease.

Rising initiatives by government and non-government organizations is also putting the pipeline development in the global cryptococcosis market on the fast track in many countries, especially in developed ones.

However, the global cryptococcosis market is currently being affected by restraining factors such as the increased mortality among cryptococcosis infected patients, which reduces the overall scope of

testing and diagnostics, and the imminent patent expiry of key drugs which will result in the large scale entry of cheaper generics.

The global cryptococcosis market is segmented into the key regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the leading share on the global cryptococcosis market for 2015, due to the rising prevalence of the infection in endemic areas of the U.S., coupled with a higher penetration of healthcare services across the country.

The region is projected to continue to dominate the global cryptococcosis market till 2024, a fact attributed to the rising numbers of the HIV infected population in the region, a highly structured and advanced healthcare industry, and well-defined reimbursement policies from public as well as private health insurance firms.

The cryptococcosis market in the Middle East and Africa is projected to expand at a substantial growth rate owing to the contribution of SubSahara African countries in terms of demand, where the count of HIV patients is exceptionally high. North America and the Middle East and Africa are projected to be highly lucrative regions in the global cryptococcosis market, while Europe, Asia Pacific, and Latin America expected to remain relatively smaller in terms of demand and growth rate.

Based on the distribution channel, the global cryptococcosis market is segmented into hospital pharmacies, retail pharmacies, drug store, and mail order pharmacies. Retail pharmacy was the leading segment in the global market on the basis of revenue, for 2015. This segment is also expected to continue dominating the market till 2024, owing to the growing contribution of long-term medication needed for successful cryptococcosis treatment.

Online purchase of drugs has been highly popular in a lot of developed economies, including the U.S. and Japan. Online pharmaceutical retailers are also generating a high volume of preference in in emerging economies such as Brazil, China, and India as well, further increasing the scope of growth for the global cryptococcosis market over the coming years.

The global cryptococcosis market is segmented on the basis of treatment, primarily into Amphotericin B, Flucytosine and Fluconazole.

Amphotericin B further segmented into Amphocin, Fungizone, and other products. Flucytosine is further segmented into Ancobon and other products. Fluconazole includes Diflucan and other products. In terms of treatment, Flucytosine was the leading segment in the global cryptococcosis market in terms of revenue for 2015, driven by its large scale adoption in the U.S. The leading players in the global cryptococcosis market so far, included Bristol-Myers Squibb Company, Janssen Biotech, (Johnson & Johnson), Abbott Laboratories, Novartis AG, Pfizer, Valeant Pharmaceuticals, Inc., Glenmark Pharmaceuticals Sigmapharm Laboratories LLC.

have Inc. Inc., and

Browse Full Press Release on Cryptococcosis Market: Press Release

About Us Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com